Transfusion Medicine Reviews
Volume 24 , Pages S7-S27 , January 2010

The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline

References 

  1. Nahirniak S, Hume H. Guidelines for the use of intravenous immune globulin for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1–S6
  2. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S9–S56
  3. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2 Suppl 1):S57–S107
  4. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S28–S50
  5. Staak A, Renner F, Suesal C, et al. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. Transplant Proc. 2008;38:3483–3485
  6. Bunchman TE, Parekh RS, Kershaw D, et al. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transpl. 1997;11:604–607
  7. Meyer SR, Ross DB, Forbes K, et al. Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery. J Thorac Cardiovasc Surg. 2007;133:1517–1523
  8. Drakos S, Kfoury A, Long JW, et al. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg. 2006;82:889–894
  9. Montgomery RA, Locke JE. ABO-incompatible transplantation: Less may be more. Transplantation. 2007;84(12 Suppl):S8–S9
  10. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256–3262
  11. Peraldi MN, Akposso K, Haymann JP, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation. 1996;62:1670–1673
  12. Anglicheau D, Loupy A, Suberbielle C, et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant. 2007;7:1185–1192
  13. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant. 2007;7:626–632
  14. Mahmoud KM, Sobh MA, El SF, et al. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution?. Eur J Pharmacol. 2007;561:202–205
  15. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346–351
  16. Thielke J, DeChristopher PJ, Sankary H, et al. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc. 2005;37:643–644
  17. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation. 2005;79:742
  18. Mahmoud K, Sobh M, El-Shenawy F, et al. Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against HLA in highly sensitized transplant candidates. Transplant Proc. 2004;36:1850–1852
  19. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin (IVIG) and thymoglobulin facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (FC) T and/or B cell cross-match positive patients. Transplantation. 2003;76:1444–1447
  20. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3:1017–1023
  21. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76:631–636
  22. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation. 2003;76:1519–1525
  23. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:758–760
  24. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc. 2002;34:1614–1616
  25. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531–1536
  26. Glotz D, Haymann JP, Niaudet P, et al. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc. 1995;27:1038–1039
  27. Tyden G, Donauer J, Wadstrom J, et al. Implementation of a protocol for ABO-incompatible kidney transplantation—A three-center experience with 60 consecutive transplantations. Transplantation. 2007;83:1153–1155
  28. Tyden G, Kumlien G, Genberg H, et al. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplantation. 2006;13:105–107
  29. Kayler L, Farber JL, Clombe B, et al. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible liver donor renal transplantation. Transplant International. 2006;19:128–139
  30. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005;5:145–148
  31. Winters JL, Gloor JM, Pineda AA, et al. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apheresis. 2004;79–85
  32. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant. 2004;4:1315–1322
  33. Gloor JM, Lager DJ, Moore SB, et al. ABO incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003;75:971–977
  34. Casadei DH, del CR, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation. 2001;71:53–58
  35. Vasilescu ER, Ho EK, Colovai AI, et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol. 2006;67:597–604
  36. Jordan SC, Vo AA, Toyoda M, et al. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transpl. 2005;9:155–161
  37. Lehrich RW, Rocha PN, Reinsmoen N, et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: Experience in renal allograft transplantation. Hum Immunol. 2005;66:350–358
  38. White NB, Greenstein SM, Cantafio AW, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation. 2004;78:772–774
  39. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation. 2003;75:1490–1495
  40. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation. 2001;72:419–422
  41. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887–895
  42. Casadei D, Rial M, Argento J, et al. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections. Transplant Proc. 1998;30:2164
  43. Jordan SC, Quartel AW, Czer LSC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral reaction in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66:800–808
  44. Casadei D, Rial M, Raimondi E, et al. Immunoglobulin i.v. high dose (IVIgHD): New therapy as a rescue treatment of grafted kidneys. Transplant Proc. 1996;28:3290–3291
  45. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: The use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;476–484
  46. Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thor Surg. 2004;78:1703–1709
  47. John R, Lietz K, Schuster M, et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg. 2003;125:578–591
  48. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;105:1214–1219
  49. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701–706
  50. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(19 Suppl):II229–II235
  51. Appel JZ, Hartwig MG, Davis RD, et al. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Human Immunology. 2005;66:378–386
  52. Urbani L, Mazzoni A, Bianco I, et al. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apheresis. 2008;23:55–62
  53. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251
  54. Vo AA, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol. 2006;1:844–852
  55. Assessment and management of immunological risk. A CCDT consensus forum. Available at: http://www.ccdt.ca/english/publications/final-pdfs/Immunologic-Risk.pdf0
  56. Treatment of end-stage organ failure in Canada 1996 to 2005, 2007 CORR annual report. Available at: (http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=PG_1110_E&cw_topic=1110&cw_rel=AR_5_E)
  57. End stage renal disease. Canadian Institute for Health Information. Available at : http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=statistics_results_topic_dialysis_e&cw_topic=Health%20Conditions&cw_subtopic=Dialysis (Accessed June 2008)
  58. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–242
  59. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  60. Karpinski M, Knoll G, Cohn A, et al. The impact of accepting living kidney donors with mild hypertension or proteinuria on transplantation rates. Am J Kidney Dis. 2006;47:317–323
  61. US. Food and Drug Adminstration . Letter to manufacturers immune globulin intravenous (human) (IGIV) required updates to product labeling. Available at: http://www.fda.gov/cber/ltr/igiv101603.htm(Accessed June 2008)
  62. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Analysis using the Banff grading schema. Transplantation. 1996;61:1586–1592
  63. Petrie JJ, Rigby RJ, Hawley CM, et al. Effect of OKT3 in steroid-resistant renal transplant rejection. Transplantation. 1995;59:347–352
  64. Nwakanma LU, Williams JA, Weiss ES, et al. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:1556–1562discussion 1562-1563
  65. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80:1019–1025
  66. Pagani FD, Dyke DB, Wright S, et al. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant. 2001;20:646–653
  67. Shah AS, Nwakanma L, Simpkins C, et al. Pretransplant panel reactive antibodies in human lung transplantation: An analysis of over 10,000 patients. Ann Thorac Surg. 2008;85:1919–1924
  68. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant. 2005;24(7 Suppl):S249–S254
  69. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg. 2000;69:1520–1524
  70. Gammie JS, Pham SM, Colson YL, et al. Influence of panel-reactive antibody on survival and rejection after lung transplantation. J Heart Lung Transplant. 1997;16:408–415
  71. Ganschow R, Englert C, Grabhorn E, et al. Hypogammaglobulinemia in pediatric liver transplant recipients. Pediatr Transplant. 2005;9:215–219
  72. Nascimbene A, Iannacone M, Brando B, et al. Acute thrombocytopenia after liver transplant: Role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol. 2007;47:651–657
  73. Echaniz-Laguna A, Battaglia F, Ellero B, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve. 2004;30:501–504
  74. Urbani L, Mazzoni A, De Simone P, et al. Treatment of antibody-mediated rejection with high-dose immunoglobulins in ABO-incompatible liver transplant recipient. Transpl Int. 2007;20:467–470
  75. Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant. 1997;11(5 Pt 1):432–437

 STATEMENT OF CONFLICT OF INTEREST: Dr L West receives research funding from the US National Institutes of Health (Grant P01-HL079067). Drs Nadine Shehata and Peter Nickerson are employees of Canadian Blood Services, as were Drs Heather Hume and John Freedman during the period of the development of these guidelines. Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or the development of the recommendations.

PII: S0887-7963(09)00090-X

doi: 10.1016/j.tmrv.2009.09.010

Transfusion Medicine Reviews
Volume 24 , Pages S7-S27 , January 2010

Article Tools